Share on StockTwits

Cytori Therapeutics (NASDAQ:CYTX) issued its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.04, StockRatingsNetwork.com reports.

Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at 1.69 on Tuesday. Cytori Therapeutics has a 1-year low of $1.46 and a 1-year high of $3.93. The stock has a 50-day moving average of $2.15 and a 200-day moving average of $2.49. The company’s market cap is $127.5 million.

CYTX has been the subject of a number of recent research reports. Analysts at Roth Capital cut their price target on shares of Cytori Therapeutics from $10.00 to $3.50 in a research note on Wednesday, August 6th. Analysts at Ascendiant Capital Markets downgraded shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 6th. They now have a $4.00 price target on the stock.

Cytori Therapeutics, Inc develops cell therapies based on autologous adipose-derived stem and regenerative cells (NASDAQ:CYTX) to treat cardiovascular disease and repair soft tissue defects.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.